Akoya Biosciences Past Earnings Performance
Past criteria checks 0/6
Akoya Biosciences's earnings have been declining at an average annual rate of -26.4%, while the Life Sciences industry saw earnings growing at 14.2% annually. Revenues have been growing at an average rate of 23.5% per year.
Key information
-26.4%
Earnings growth rate
54.9%
EPS growth rate
Life Sciences Industry Growth | 21.5% |
Revenue growth rate | 23.5% |
Return on equity | -271.3% |
Net Margin | -64.7% |
Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Akoya Biosciences, Inc. (NASDAQ:AKYA) Just Reported, And Analysts Assigned A US$5.42 Price Target
Aug 09Market Might Still Lack Some Conviction On Akoya Biosciences, Inc. (NASDAQ:AKYA) Even After 31% Share Price Boost
Jun 27Is Akoya Biosciences (NASDAQ:AKYA) A Risky Investment?
Jun 24We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Akoya Biosciences, Inc.'s (NASDAQ:AKYA) CEO For Now
May 29Investors Continue Waiting On Sidelines For Akoya Biosciences, Inc. (NASDAQ:AKYA)
May 10Is Akoya Biosciences (NASDAQ:AKYA) Weighed On By Its Debt Load?
Feb 28Investors Still Aren't Entirely Convinced By Akoya Biosciences, Inc.'s (NASDAQ:AKYA) Revenues Despite 31% Price Jump
Nov 25Akoya Biosciences Seeks Growth Despite Higher Operating Losses
May 30Akoya Biosciences, Inc. (NASDAQ:AKYA) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?
May 11Akoya Biosciences and AstraZeneca ink collaboration agreement
Jun 04Revenue & Expenses Breakdown
How Akoya Biosciences makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Jun 24 | 93 | -60 | 74 | 19 |
31 Mar 24 | 94 | -68 | 79 | 21 |
31 Dec 23 | 97 | -63 | 82 | 22 |
30 Sep 23 | 91 | -71 | 84 | 24 |
30 Jun 23 | 85 | -76 | 88 | 25 |
31 Mar 23 | 79 | -73 | 85 | 24 |
31 Dec 22 | 75 | -71 | 80 | 23 |
30 Sep 22 | 70 | -69 | 78 | 22 |
30 Jun 22 | 64 | -63 | 72 | 21 |
31 Mar 22 | 60 | -51 | 61 | 18 |
31 Dec 21 | 55 | -44 | 51 | 16 |
30 Sep 21 | 52 | -34 | 39 | 13 |
30 Jun 21 | 48 | -28 | 31 | 11 |
31 Mar 21 | 44 | -28 | 26 | 10 |
31 Dec 20 | 42 | -22 | 24 | 10 |
31 Dec 19 | 42 | -18 | 26 | 9 |
Quality Earnings: AKYA is currently unprofitable.
Growing Profit Margin: AKYA is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: AKYA is unprofitable, and losses have increased over the past 5 years at a rate of 26.4% per year.
Accelerating Growth: Unable to compare AKYA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: AKYA is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (-10.8%).
Return on Equity
High ROE: AKYA has a negative Return on Equity (-271.25%), as it is currently unprofitable.